2023-01-24 14:00:00

Riverside Partners' Portfolio Company Syner-G Acquires RMC

Logo PR Newswire
PR Newswire

BOSTON, Jan. 24, 2023 /PRNewswire/ -- Syner-G BioPharma Group ("Syner-G" or the "Company"), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, has acquired RMC Pharmaceutical Solutions ("RMC"). Based in Boulder, CO, RMC supports the outsourced CMC and Quality needs of pharmaceutical and biotechnology companies across multiple therapeutic areas. Syner-G is a portfolio company of Riverside Partners, a Boston-based private equity firm.

Since Riverside Partners' investment in Syner-G, the Company has grown significantly and expanded its service offering for pharmaceutical and biotechnology clients. RMC is Syner-G's second add-on acquisition within the last year. The acquisition of RMC provides additional depth to Syner-G's suite of pharmaceutical science services, adding impressive development experience in all biologic modalities including cell and gene therapy. The combined team offers a broad range of process and analytical development services, regulatory strategy, regulatory submission support, and quality management services.

"We are excited to support the combination of Syner-G and RMC," said Craig Stern, a General Partner at Riverside Partners. "Similar to Syner-G, RMC has an outstanding reputation in the marketplace, an impressive list of clients, and an excellent team of highly qualified, experienced, and dedicated employees. By adding RMC's exceptional capabilities and employees, Syner-G is building on its long-standing commitment to provide unparalleled expertise and service to customers."

Both Syner-G and RMC have strong track records of consistent growth and success in providing customized solutions to support the development of life-enhancing and lifesaving therapeutics. The combination enhances Syner-G's ability to deliver the highest caliber CMC services to pharmaceutical and biotechnology companies of all sizes globally.

"I am very pleased to welcome the RMC team to Syner-G," said Ron Kraus, Chief Executive Officer of Syner-G BioPharma Group. "RMC's biologics experience and their 'Responsive, Measured, and Creative' approach to product development fits perfectly with Syner-G's vision to be the trusted development partner to our clients, recognized globally for our strategic, innovative, and scientifically-driven approach."

"Our clients have come to expect high levels of critical thinking, informed by the best science and engineering, applied reliably, nimbly, and phase appropriately to solve problems and advance their programs," said Scott Rudge, Co-Founder, Chairman, and Chief Operating Officer of RMC. "We know that's exactly what they will continue to receive from Syner-G, and I'm delighted to continue to play a key role in the combined business." Timothy Joy, Co-Founder, President, and Chief Executive Officer of RMC added, "In addition to the obvious benefits the combined organization presents to RMC's clients, I'm excited about the future opportunities that being part of a larger organization offers to RMC's employees."

Financial terms of the transaction were not disclosed.

About Syner-G BioPharma Group

Based in Boston, MA, Syner-G is a leading provider of customized CMC, regulatory strategy, medical writing, regulatory submissions and publishing services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle. For more information, visit www.synergbiopharma.com.

About RMC Pharmaceutical Solutions

Based in Boulder, CO, RMC specializes in providing CMC and quality management services for the pharmaceutical and biotech sector. For more information, visit www.rmcpharma.com.

About Riverside Partners

Founded in 1989, Riverside Partners is a middle market private equity firm with total capital commitments of $1.6 billion raised since inception. The firm focuses on growth-oriented companies in the technology and healthcare industries. Riverside Partners is particularly experienced at partnering with founders, owners and management teams, and it brings substantial domain expertise and operating experience to its portfolio companies. For more information, visit www.riversidepartners.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/riverside-partners-portfolio-company-syner-g-acquires-rmc-301728814.html

SOURCE Riverside Partners

Logo PR Newswire
HealthPress Release2023-01-19 17:00:00
Expands Expertise in Biologics and Builds Scale in CMC and Quality Consulting BOSTON, Jan. 19, 2023 /PRNewswire-PRWeb/ -- Syner-G BioPharma Group (Syner-G),...

Logo PR Newswire
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at...

Logo PR Newswire
HealthPress Release2023-01-24 10:56:00
Two successful exits – Syndesi and BioPhero Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and...

Logo PR Newswire
HealthPress Release2023-01-24 12:17:00
Emerging Market Leader Continues to Execute on Successful Growth Strategy JACKSONVILLE, Fla., Jan. 24, 2023 /PRNewswire/ -- ReviveHealth, a whole health and...

Logo PR Newswire
HealthPress Release2023-01-23 20:00:00
WOONSOCKET, R.I., Jan. 23, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS ) today announced two executive appointments. David Joyner will rejoin the company as...

Logo PR Newswire
HealthPress Release2023-01-23 17:00:00
Combination delivers on ScionHealth's commitment to provide patients with world-class care close to home. LOUISVILLE, Ky., Jan. 23, 2023 /PRNewswire/ --...

Logo GlobeNewswire
SciencePress Release2023-01-23 14:20:00
The Company is expected to evaluat e alternatives to address potential short sales issue TEL AVIV, Israel, Jan. 23, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....

Logo EIN Presswire
HealthPress Release2023-01-23 09:44:17
Pharmaceutical Container Market Growth 2023 Major players profiled in the report include Gerresheimer, AptarGroup, Berry Plastics Group, Amcor Limited, Alpha...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:00:00
TORONTO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG. |. OTCQB: PSYGF ) (Psyence or the Company ), a life science biotechnology company...

Logo GlobeNewswire
SciencePress Release2023-01-23 18:25:00
Announced Earlier Today -Notice Received from ANDA Filer for FIRDAPSE CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc....

Logo GlobeNewswire
SciencePress Release2023-01-24 11:27:00
Company Announcement Net sales of DARZALEX in 2022 totaled USD 7, 977 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc....

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-23 23:55:27
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103 On track to commence patient enrollment during the first half 2023 ADELAIDE,...

Logo PR Newswire
TechnologyPress Release2023-01-24 13:57:00
QuartzBio's suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker,...

Logo GlobeNewswire
SciencePress Release2023-01-23 14:20:00
Partnership Will Provide Pharmaceutical Grade Cannabinoid Active Ingredients to the Largest Pharmaceutical and Consumer Goods Names in the Industry BUFFALO,...

Logo PR Newswire
HealthPress Release2023-01-23 16:56:00
HARLEYSVILLE, Pa., Jan. 23, 2023 /PRNewswire/ -- Colorcon, Inc., a global leader in pharmaceutical film coatings and specialty excipients, today announces...

Logo GlobeNewswire
SciencePress Release2023-01-23 14:22:00
NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the Company or Bioasis ), a multi-asset rare and...

Logo Nasdaq
Business / FinanceBy Fintel2023-01-23 17:17:40
Fintel reports that EcoR1 Capital, LLC has filed a 13G form with the SEC disclosing ownership of 4,478,050 shares of Revolution Medicines Inc ( RVMD ). This...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 13:13:00
medZERO, a fintech company that enables on-demand, automatic, interest-free payment for out-of-pocket healthcare expenses, has added six health and benefits...

Logo GlobeNewswire
SciencePress Release2023-01-23 21:11:00
NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:00:00
NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing...